Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology); Director, Yale Cancer Center Tissue Microarray Facility, Pathology; Director, Yale Pathology Tissue Services, Pathology; Director, Physician Scientist Training Program, Pathology Research
Troplex™ Assay for Breast Cancer Biomarkers
The new Troplex™ assay from Yale Pathology Laboratories uses novel technology to quantitatively measure two breast cancer biomarkers – HER2 and TROP2 – both of which are targets for antibody drug conjugate (ADC) therapies in patients with advanced/metastatic breast cancer. The two therapies, Trastuzumab Deruxtecan (TDXd), which targets HER2, and Sacituzumab Govitecan (SG), which targets TROP2, can then selected based on a quantitative score.
Until the development of the new Troplex™ assay, oncologists could choose between TDXd or SG for patients with advanced/metastatic breast cancer. But the big question is: Which treatment should you prescribe first?
The Troplex™ assay provides defined answers through quantitative measurements of both targets, comparing the two biomarkers to determine which is higher. The Troplex™ assay indicates which biomarker dominates the tumor therefore indicating which drug therapy to administer first.
Oncologists want to prescribe the best treatment option [for their patients] first—the one that’s most likely to work. Unfortunately, the decision is not always clear. The Troplex™ assay provides a quantitative result to assist the oncologist in deciding which ADC therapy to prescribe in breast cancer.
Superior Customer Service
- Experienced pathologists and technical staff are available for timely consultation
- Immediate online access to case reports using Yale Pathology RELAY web portal
- Dedicated Physician Liaison assigned to your account
- Direct supply of sample kits containing instructions to help you with tissue sampling and prepaid FedEx shipping
Contact
Download Information Sheet
Click here to download a PDF Information Sheet for the Troplex™ Assay for Breast Cancer Biomarkers service at Yale Pathology Labs.
Learn more:
Stephanie Weirsman, Director, Reference Services Business Development